Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

specialty care

- PMLiVE

Best practice RWE approaches to support economic modelling for HTA

How can real-world evidence (RWE) support health technology assessment (HTA)? Join the live webinar on Thursday 3rd October at 1.00pm (BST), featuring panellists from Mtech Access, Arcturis, and Delta Hat.

Petauri Evidence

- PMLiVE

Bringing Clinicians Together for Oncology Education at ESMO 2024

ESMO 2024 comes with the debut of 2 new, exciting symposia hosted by the MedscapeLIVE! team. The symposia build on nearly 30 years of Medscape’s experience and excellence in both...

Medscape Education

Bayer symbol

Bayer and NextRNA Therapeutics enter oncology partnership worth $547m

The companies will advance small molecule therapeutics against a new class of targets for cancer

- PMLiVE

FDA approves Citius’ immunotherapy Lymphir to treat cutaneous T-cell lymphoma

The rare type of non-Hodgkin lymphoma currently affects about 40,000 people in the US

- PMLiVE

UK study reveals previously unknown genetic causes of colorectal cancer

The third most commonly diagnosed cancer globally is responsible for more than 44,000 new cases in the UK every year

- PMLiVE

Sanofi shares positive phase 3 results for Sarclisa in newly diagnosed multiple myeloma

More than 180,000 new cases of the haematological malignancy are diagnosed globally every year

- PMLiVE

Innovative Trials partners with GOSH and Oliver Patch for childhood cancer research

Childhood cancers, including leukaemia and lymphoma, affect 400,000 children globally every year

- PMLiVE

UCLA launches study of personalised cancer vaccine in paediatric brain tumours

H3 G34-mutant diffuse hemispheric gliomas are brain tumours commonly found in adolescents and young adults

- PMLiVE

Eisai and SEED enter molecular glue degrader partnership worth up to $1.5bn

The companies are aiming to develop candidates for multiple neurodegeneration and oncology targets

- PMLiVE

Researchers develop immunotherapy to prevent prostate cancer treatment resistance

The second-most common cancer in the UK affects more than 52,000 men every year

- PMLiVE

ALX Oncology’s evorpacept shows promise as gastric cancer combination treatment

More than 6,500 new diagnoses of gastric cancer are made in the UK every year

- PMLiVE

Innovative Trials Announces New Charity Partnerships

Innovative Trials, a global patient recruitment and retention company, has just announced GOSH Charity and Oliver Patch Project as their charity partners of the year

Innovative Trials

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links